Fibroblast growth factor 19 in patients with bile acid diarrhoea: A prospective comparison of FGF19 serum assay and SeHCAT retention

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 967-976

  Pattni, S S ^a   Brydon, W G ^b   Dew, T ^c   Johnston, I M ^a   Nolan, J D ^a   Srinivas, M ^d   Basumani, P ^d   Bardhan, K D ^d   Walters, J R F ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; BILE ACID; CHOLEST 4 EN 3 ONE; COLESEVELAM; COLESTYRAMINE; FIBROBLAST GROWTH FACTOR 19; TAUROSELCHOLIC ACID SE 75; UNCLASSIFIED DRUG;

AGE; AREA UNDER THE CURVE; ARTICLE; BILE ACID BLOOD LEVEL; BODY MASS; CHRONIC DIARRHEA; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY BILE ACID DIARRHEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SECONDARY BILE ACID DIARRHEA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; BILE ACIDS AND SALTS; BIOLOGICAL ASSAY; CHOLESTENONES; DIARRHEA; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SELENIUM RADIOISOTOPES; TAUROCHOLIC ACID;

EID: 84884904019     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12466     Document Type: Article

References (35)

1. Pattni SS, Walters JRF,. Recent advances in the understanding of bile acid malabsorption. Br Med Bull 2009; 92: 79-93.
2. Hofmann AF, Poley JR,. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med 1969; 281: 397-402.
3. Walters JRF, Pattni SS,. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010; 3: 349-57.
4. Fromm H, Malavolti M,. Bile acid-induced diarrhoea. Clin Gastroenterol 1986; 15: 567-82.
5. Walters JR,. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol 2010; 4: 561-7.
6. Wedlake L, A'Hern R, Thomas K, Walters JRF, Andreyev HJN,. Systematic review: the prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Aliment Pharmacol Ther 2009; 30: 707-17.
7. Sciarretta G, Vicini G, Fagioli G, et al,. Use of 23-selena-25- homocholyltaurine to detect bile acid malabsorption in patients with ileal dysfunction or diarrhea. Gastroenterology 1986; 91: 1-9.
8. Merrick MV, Eastwood MA, Ford MJ,. Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention. Br Med J (Clin Res Ed) 1985; 290: 665-8.
9. Borghede MK, Schlutter JM, Agnholt JS, et al,. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur J Intern Med 2011; 22: e137-40.
10. Kurien M, Evans KE, Leeds JS, et al,. Bile acid malabsorption: an under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011; 46: 818-22.
11. Gracie D, Kane J, Mumtaz S, et al,. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538.
12. Brydon WG, Nyhlin H, Eastwood MA, Merrick MV,. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 117-23.
13. Sauter GH, Munzing W, von RC, Paumgartner G,. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3- one in serum. Dig Dis Sci 1999; 44: 14-9.
14. Brydon WG, Culbert P, Kingstone K, et al,. An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea. Can J Gastroenterol 2011; 25: 319-23.
15. Wong BS, Camilleri M, Carlson P, et al,. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15.
16. Walters JRF, Tasleem AM, Omer OS, et al,. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
17. Hofmann AF, Mangelsdorf DJ, Kliewer SA,. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009; 7: 1151-4.
18. Inagaki T, Choi M, Moschetta A, et al,. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
19. van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M,. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut 1991; 32: 500-3.
20. van Tilburg AJ, de Rooij FW, van den Berg JW, van Blankenstein M,. Primary bile acid malabsorption: a pathophysiologic and clinical entity? Scand J Gastroenterol Suppl 1992; 194: 66-70.
21. Bajor A, Kilander A, Fae A, et al,. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur J Gastroenterol Hepatol 2006; 18: 397-403.
22. Jung D, Inagaki T, Gerard RD, et al,. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res 2007; 48: 2693-700.
23. Pai R, French D, Ma N, et al,. Antibody-mediated inhibition of fibroblast growth factor-19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci 2012; 126: 446-56.
24. Wong BS, Camilleri M, Carlson PJ, et al,. A Klotho-beta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-42.
25. Pattni SS, Brydon WG, Dew T, Walters JRF,. Fibroblast growth factor 19 and 7a-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Trans Gastroenterol 2012; 3: e18.
26. Lundasen T, Galman C, Angelin B, Rudling M,. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
27. Galman C, Angelin B, Rudling M,. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580-8.
28. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al,. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
29. Rao AS, Wong BS, Camilleri M, et al,. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58.
30. Angelin B, Bjorkhem I, Einarsson K, Ewerth S,. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest 1982; 70: 724-31.
31. Bajor A, Ung KA, Ohman L, et al,. Indirect evidence for increased mechanosensitivity of jejunal secretomotor neurones in patients with idiopathic bile acid malabsorption. Acta Physiol (Oxf) 2009; 197: 129-37.
32. Sadik R, Abrahamsson H, Ung K-A, Stotzer P-O,. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004; 99: 711-8.
33. Kuganolipava S, Dew T, Pattni SS, et al,. Rapid normalisation of fasting serum fibroblast growth factor (FGF) 19 following bariatric surgery. Gut 2009; 58 (Suppl II): A121.
34. Kir S, Beddow SA, Samuel VT, et al,. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-4.
35. Johnston IM, Nolan JD, Dew T, Shapiro D, Walters JRF,. A new therapy for chronic diarrhea? A proof of concept study of the FXR agonist obeticholic acid in patients with primary bile acid diarrhea. Gastroenterology 2013; 144: S-60.